Systemic Erythropoietin Injection in Patients Having Optic Atrophy

Optic Atrophy Clinical Trial

Official title:

Systemic Erythropoietin Injection in Patients Having Optic Atrophy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04680143
• Other study ID #: 0304845
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 1, 2020
• Est. completion date: March 30, 2021

Study information

• Verified date: July 2021
• Source: Alexandria University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.

Description:

The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Follow up after one month and three months by recording visual acuity and electro physiological studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 30, 2021
• Est. primary completion date: March 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Post papilledemic optic atrophy patients

Exclusion Criteria:

• Refuse to give an informed consent

Related Conditions & MeSH terms

• Atrophy
• Optic Atrophy

Intervention

Drug:
• Systemic erythropoietin injection
Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).

Locations

Country	Name	City	State
Egypt	Alexandria Faculty of Medicine	Alexandria

Sponsors (1)

Lead Sponsor	Collaborator
Alexandria University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual acuity	VIsual acuity assessed at the follow up	3 months
Primary	Pattern visual evoked Potential .	Pattern visual evoked Potential .in both eyes to use data of the normal fellow eye as patients' internal control	3 months
Primary	Pattern electroretinogram	Pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control	3 months